Side effects of antidepressants during long-term use in a naturalistic setting

European Neuropsychopharmacology

Volumn 23, Issue 11, 2013, Pages 1443-1451

  Bet, Pierre M ^a,b   Hugtenburg, Jacqueline G ^a   Penninx, Brenda W J H ^a,b,c,d   Hoogendijk, Witte J G ^a,b,e  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Antidepressants; Anxiety; Depression; Naturalistic setting; Side effects

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; FLUOXETINE; HYPERICUM PERFORATUM EXTRACT; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; AGED; ANTICHOLINERGIC SYNDROME; ANXIETY DISORDER; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONSTIPATION; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE; MUSCLE SPASM; MUSCLE TWITCH; NATURALISTIC INQUIRY; NAUSEA; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RESTLESSNESS; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SWEATING; WEIGHT GAIN; XEROSTOMIA;

ANTIDEPRESSANTS; ANXIETY; DEPRESSION; NATURALISTIC SETTING; SIDE EFFECTS;

ADULT; AGED; AGING; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NETHERLANDS; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; YOUNG ADULT;

EID: 84886786630     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.05.001     Document Type: Article

References (40)

1. American Psychiatric Association, 2001. Diagnostic and Statistical Manual of Mental Disorders, fourth edition, Washington.
2. Anderson I.M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J. Affect. Disord. 2000, 58:19-36.
3. Barak Y., Swartz M., Levy D., Weizman R. Age-related differences in the side effect profile of citalopram. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:545-548.
4. Carroll D.G., Kelley K.W. Use of antidepressants for management of hot flashes. Pharmacotherapy 2009, 29:1357-1374.
5. Coupland C., Dhiman P., Morriss R., Arthur A., Barton G., Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 2011, 343:d4551.
6. Davidson J.R., Foa E.B., Connor K.M., Churchill L.E. Hyperhidrosis in social anxiety disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26:1327-1331.
7. Draper B., Berman K. Tolerability of selective serotonin reuptake inhibitors: issues relevant to the elderly. Drugs Aging 2008, 25:501-519.
8. Gartlehner G., Thieda P., Hansen R.A., Gaynes B.N., veaugh-Geiss A., Krebs E.E., Lohr K.N. Comparative risk for harms of second-generation antidepressants: a systematic review and meta-analysis. Drug Saf. 2008, 31:851-865.
9. Hansen R., Gaynes B., Thieda P., Gartlehner G., veaugh-Geiss A., Krebs E., Lohr K. Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiatr. Serv. 2008, 59:1121-1130.
10. Kasper S., Caraci F., Forti B., Drago F., Aguglia E. Efficacy and tolerability of Hypericum extract for the treatment of mild to moderate depression. Eur. Neuropsychopharmacol. 2010, 20:747-765.
11. Kasper S., Volz H.P., Moller H.J., Dienel A., Kieser M. Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression-a double-blind, randomized, placebo controlled long-term trial. Eur. Neuropsychopharmacol. 2008, 18:803-813.
12. Kessler R.C., Andrews G., Colpe L.J., Hiripi E., Mroczek D.K., Normand S.L., Walters E.E., Zaslavsky A.M. Short screening scales to monitor population prevalences and trends in non-specific psychological distress. Psychol. Med. 2002, 32:959-976.
13. Kessler R.C., Barker P.R., Colpe L.J., Epstein J.F., Gfroerer J.C., Hiripi E., Howes M.J., Normand S.L., Manderscheid R.W., Walters E.E., Zaslavsky A.M. Screening for serious mental illness in the general population. Arch. Gen. Psychiatry 2003, 60:184-189.
14. Klauenberg S., Maier C., Assion H.J., Hoffmann A., Krumova E.K., Magerl W., Scherens A., Treede R.D., Juckel G. Depression and changed pain perception: hints for a central disinhibition mechanism. Pain 2008, 140:332-343.
15. Lingam R., Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr. Scand. 2002, 105:164-172.
16. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand. Suppl. 1987, 334:1-100.
17. Mackay F.J., Dunn N.R., Wilton L.V., Pearce G.L., Freemantle S.N., Mann R.D. A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiol. Drug Saf. 1997, 6:235-246.
18. Mackay F.R., Dunn N.R., Martin R.M., Pearce G.L., Freemantle S.N., Mann R.D. Newer antidepressants: a comparison of tolerability in general practice. Br. J. Gen. Pract. 1999, 49:892-896.
19. Mann R.D., Wilton L.V., Pearce G.L., Mackay F.J., Dunn N.R. Prescription-event monitoring (PEM) in 1996-a method of non-interventional observational cohort pharmacovigilance. Pharmacoepidemiol. Drug Saf. 1997, 6(Suppl. 3):S5-S11.
20. Marcy T.R., Britton M.L. Antidepressant-induced sweating. Ann. Pharmacother. 2005, 39:748-752.
21. Meltzer C.C., Smith G., DeKosky S.T., Pollock B.G., Mathis C.A., Moore R.Y., Kupfer D.J., Reynolds C.F. Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging. Neuropsychopharmacology 1998, 18:407-430.
22. Naranjo C.A., Herrmann N., Mittmann N., Bremner K.E. Recent advances in geriatric psychopharmacology. Drugs Aging 1995, 7:184-202.
23. Papanikolaou P.N., Churchill R., Wahlbeck K., Ioannidis J.P. Safety reporting in randomized trials of mental health interventions. Am. J. Psychiatry 2004, 161:1692-1697.
24. Penninx B.W., Beekman A.T., Smit J.H., Zitman F.G., Nolen W.A., Spinhoven P., Cuijpers P., De Jong P.J., Van Marwijk H.W., Assendelft W.J., Van Der M.K., Verhaak P., Wensing M., de G.R., Hoogendijk W.J., Ormel J., van D.R. The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods. Int. J. Methods Psychiatr. Res. 2008, 17:121-140.
25. Rief W., Nestoriuc Y., von Lilienfeld-Toal A., Dogan I., Schreiber F., Hofmann S.G., Barsky A.J., Avorn J. Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis. Drug Saf. 2009, 32:1041-1056.
26. Rolls B.J., Fedoroff I.C., Guthrie J.F. Gender differences in eating behavior and body weight regulation. Health Psychol. 1991, 70:133-142.
27. Rush A.J., Gullion C.M., Basco M.R., Jarrett R.B., Trivedi M.H. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol. Med. 1996, 26:477-486.
28. Schueler Y.B., Koesters M., Wieseler B., Grouven U., Kromp M., Kerekes M.F., Kreis J., Kaiser T., Becker T., Weinmann S. A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatr. Scand. 2011, 123:247-265.
29. Serretti A., Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J. Clin. Psychiatry 2010, 71:1259-1272.
30. Stahl S.M., Grady M.M., Moret C., Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS.Spectr. 2005, 10:732-747.
31. Stone M., Laughren T., Jones M.L., Levenson M., Holland P.C., Hughes A., Hammad T.A., Temple R., Rochester G. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 2009, 339:b2880.
32. Thase M.E., Gelenberg A., Kornstein S.G., Kocsis J.H., Trivedi M.H., Ninan P., Li T., Pedersen R., Keller M. Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT study. J. Psychiatr. Res. 2011, 45:412-420.
33. Trindade E., Menon D., Topfer L.A., Coloma C. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ 1998, 159:1245-1252.
34. Uher R., Farmer A., Henigsberg N., Rietschel M., Mors O., Maier W., Kozel D., Hauser J., Souery D., Placentino A., Strohmaier J., Perroud N., Zobel A., Rajewska-Rager A., Dernovsek M.Z., Larsen E.R., Kalember P., Giovannini C., Barreto M., McGuffin P., Aitchison K.J. Adverse reactions to antidepressants. Br. J. Psychiatry 2009, 195:202-210.
35. van der Lem R., van der Wee N.J., van V.T., Zitman F.G. The generalizability of antidepressant efficacy trials to routine psychiatric out-patient practice. Psychol. Med. 2011, 41:1353-1363.
36. Watanabe N., Omori I.M., Nakagawa A., Cipriani A., Barbui C., McGuire H., Churchill R., Furukawa T.A. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. CNS Drugs 2010, 24:35-53.
37. WHO, 2012. Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical (ATC) Classification. (accessed May 2012). http://www.whocc.no/atcddd/.
38. Wilting I., Heerdink E.R., Mersch P.P., den Boer J.A., Egberts A.C., Nolen W.A. Association between lithium serum level, mood state, and patient-reported adverse drug reactions during long-term lithium treatment: a naturalistic follow-up study. Bipolar Disord. 2009, 11:434-440.
39. Wittchen H.U. Reliability and validity studies of the WHO-Composite International Diagnostic Interview (CIDI): a critical review. J. Psychiatr. Res. 1994, 28:57-84.
40. Zimmerman M., Mattia J.I., Posternak M.A. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?. Am. J. Psychiatry 2002, 159:469-473.